Accessibility Menu
 
Protara Therapeutics logo

Protara Therapeutics

(NASDAQ) TARA

Current Price$5.21
Market Cap$281.78M
Since IPO (2020)-83%
5 Year-67%
1 Year+22%
1 Month-18%

Protara Therapeutics Financials at a Glance

Market Cap

$281.78M

Revenue (TTM)

$0.00

Net Income (TTM)

$57.44M

EPS (TTM)

$-1.34

P/E Ratio

-3.90

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$5.21

Volume

13,642

Open

$4.93

Previous Close

$5.21

Daily Range

$4.93 - $5.21

52-Week Range

$2.77 - $7.82

TARA News

TARA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protara Therapeutics

Industry

Biotechnology

Employees

51

CEO

Jesse Shefferman, MBA

Headquarters

New York City, NY 10010, US

TARA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-32%

Return on Capital

-33%

Return on Assets

-27%

Earnings Yield

-25.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$281.78M

Shares Outstanding

54.08M

Volume

13.64K

Short Interest

0.00%

Avg. Volume

1.13M

Financials (TTM)

Gross Profit

$362.00K

Operating Income

$64.55M

EBITDA

$64.19M

Operating Cash Flow

$56.37M

Capital Expenditure

$94.00K

Free Cash Flow

$56.46M

Cash & ST Invst.

$155.55M

Total Debt

$3.36M

Protara Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$93.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$281.78M

N/A

Market Cap/Employee

$10.06M

N/A

Employees

28

N/A

Net Income

$17.31M

-35.5%

EBITDA

$19.08M

-34.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$152.19M

-8.2%

Accounts Receivable

$1.26M

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.12M

-37.0%

Short Term Debt

$1.24M

+10.5%

Return on Assets

-27.42%

N/A

Return on Invested Capital

-32.51%

N/A

Free Cash Flow

$16.97M

-82.4%

Operating Cash Flow

$16.95M

-82.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OBIOOrchestra BioMed Holdings, Inc.
$4.25+4.42%
PRLDPrelude Therapeutics Incorporated
$3.42+11.40%
OABIOmniAb, Inc.
$1.57+0.64%
MDWDMediWound Ltd.
$16.11+4.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$174.36+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.15+0.09%
TSLATesla
$371.35+0.05%

Questions About TARA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.